Aura Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 27, 2024

AURA$7.66+16.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	December 31, 2023	December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$41,063	$121,582
Marketable securities	185,087	67,229
Restricted cash and deposits	19	20
Prepaid expenses and other current assets	5,625	7,871
Total current assets	231,794	196,702
Restricted cash and deposits, net of current portion	768	768
Right of use assets - operating lease	18,854	20,671
Other long-term assets	509	423
Property and equipment, net	3,150	5,371
Total Assets	$255,075	$223,935
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	1,787	2,921
Short-term operating lease liability	2,687	2,963
Accrued expenses and other current liabilities	7,883	4,573
Total current liabilities	12,357	10,457
Long-term operating lease liability	16,870	17,895
Total Liabilities	29,227	28,352
Commitments and Contingencies (Note 12)
Stockholders’ Equity:
Common stock, $0.00001 par value, 150,000,000 authorized at December 31, 2023 and December 31, 2022, and 49,350,788 and 37,771,918 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	—	—
Additional paid-in capital	512,617	406,555
Accumulated deficit	(287,308)	(210,900)
Accumulated other comprehensive loss	539	(72)
Total Stockholders’ Equity	225,848	195,583
Total Liabilities and Stockholders’ Equity	$255,075	$223,935

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.